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Background: The prognostic factors of thoracic esophageal squamous carcinoma with cervical lymph nodal
metastasis (CLNM) have not been specifically investigated. This study was performed to analyze the efficacy and
prognostic factors of chemoradiotherapy for thoracic esophageal carcinoma with CLNM alone.
Methods: From 2002 to 2011, 139 patients with inoperable esophageal cancer who underwent chemoradiotherapy
at the Sun Yat-Sen University were retrospectively analyzed. Median radiation doses were 60 Gy (range: 50–68 Gy).
Univariate and multivariate analyses were performed to compare overall survival (OS) and progression-free
survival (PFS).
Results: The 1- and 3-year OS rates were 68.2% and 27.9%, respectively. The 1- and 3-year PFS rates were 51.9%
and 20.1%, respectively. The multivariate analysis demonstrated that response to treatment, T stage, pathological
grade, and laterality of cervical lymph nodal metastases were independent prognostic factors for thoracic
esophageal carcinoma with CLNM.
Conclusions: Concurrent chemoradiotherapy is an important and hopeful treatment option for patients with
esophageal cancer with CLNM alone. Our study has revealed that response to treatment, T stage, pathological
grade and laterality of cervical lymph nodal metastases are significant prognostic factors for long-term survival.
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Esophageal cancer is an aggressive disease and has a li-
ability of lymphatic and hematogenous dissemination. In
addition, the prognosis of esophageal cancer is poor, and
the 5-year survival rate of patients with distant metasta-
sis is only 3% [1]. If distant metastasis occurs, the oppor-
tunity to operate is lost. For patients with inoperable
esophageal cancer, chemoradiotherapy is the mainstay of* Correspondence: liumengzhong@126.com
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unless otherwise stated.treatment. Although cervical lymph nodal metastases were
designated as stage IV according the 6th American Joint
Committee on Cancer (AJCC) staging system for esopha-
geal carcinoma, the long-term survival data of patients
with stage IV disease is varied. It has been reported that
long-term survival might be achievable in patients with
cervical lymph nodal metastases [2].
Well-known prognostic factors of esophageal cancer
are TNM stage, tumor length (for early stage esophageal
cancer) [3], concurrent chemotherapy, histopathological
grading, sex, and age [4,5]. The efficacy and prognosis of
thoracic esophageal squamous carcinoma with cervical
lymph nodal metastasis (CLNM) alone, have not been
specifically determined.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to explore the prognostic factors that are associated with
overall survival (OS) and progression-free survival (PFS)
in patients with thoracic esophageal squamous carcinoma
with CLNM, who were treated with chemoradiotherapy.
Methods
Patient population
Between February 2002 and December 2011, 139 patients
who were diagnosed with esophageal cancer with cervical
lymph nodal metastases alone at Sun Yat-sen University
Cancer Center, were retrospectively studied. Each patient
had histologically confirmed squamous cell carcinoma of
the esophagus, was unable to undergo radical resection,
and was treated with radiotherapy plus chemotherapy.
The pretreatment evaluation consisted of endoscopy, bar-
ium esophagography and a computed tomography (CT)
scan of the abdomen and thorax. Endoscopic ultrasound
has only been available since 2006. Bone scans were
performed if clinically indicated. The 6th AJCC staging
system was used in this study. The criteria for lymph
node positivity on the CT scan were either (1) short axis
size >10 mm, (2) lymph node with infiltrative margin, or
(3) central necrosis. According to the 6th AJCC classifi-
cation, 54 patients with upper third thoracic cancer and
cervical nodal metastases were staged as IVa, and the
remaining 85 patients were staged as IVb.
This study was approved by the institutional review
board (IRB) of the Cancer Center, Sun Yat-sen University.
Written informed consent was obtained from all the pa-
tients in accordance with the regulations of the IRB.
Treatment details
Radiotherapy was delivered with 6–10 MV photons once
daily, five times a week (except weekends and public hol-
idays), with a daily dose of 1.8-2 Gy. The total radiother-
apy dose was <60 Gy in 45 patients and ≥60 Gy in 94
patients. The majority of patients (131) received three-
dimensional conformal radiotherapy and the remaining
eight patients received intensity-modulated radiotherapy
(IMRT). The primary gross tumor volume (GTV-P) in-
cluded esophageal lesions found on the radiograph and the
gross tumor volume for the affected lymph nodes (GTV-
N) was determined. The conformal primary tumor volume
(CTV-P) included the GTV-P with a 3-cm margin (cranio-
caudal direction) and a 0.5-cm margin (lateral and anter-
ior–posterior directions). The CTV of the upper-third of
the squamous cell carcinoma (SCC) encompassed the bi-
lateral supraclavicular region.
Among the 139 patients, 29 received induction chemo-
therapy plus concurrent chemoradiotherapy. The other
110 patients received concurrent chemoradiotherapy. The
induction chemotherapy was two cycles of docetaxel
(70 mg/m2) and cisplatin (80 mg/m2). Fifty patients weretreated with two cycles of docetaxel (60 mg/m2) and cis-
platin (80 mg/m2) delivered on days 1 and 22 of radio-
therapy [6]. Twenty-two patients received at least four
cycles of docetaxel (30 mg/m2) and cisplatin (35 mg/m2)
per week. Another 44 were treated with two cycles of
60 mg/m2 of cisplatin administered on days 1 and 29 and
300 mg/m2/24 h of 5-FU administered on days 1–3 and
days 29–31 [7]. The remaining 23 patients received other
regimens of chemotherapy such as navelbine plus cisplatin.
Toxicity and response assessment
The evaluation of acute treatment toxicities consisted of
history and physical examination, documentation of per-
formance status, complete blood count, and toxicities
scoring. A routine barium swallow was performed by the
radiation oncologist at doses of 20, 40 and 60 Gy. One
day before starting the next chemotherapy cycle, a full
blood count and serum chemistry was carried out. The
acute toxicity of radiotherapy and chemotherapy were
evaluated according to CTC version 2.0. The treatment
effect was assessed at one month after finishing treatment,
and included physical examination and history, endos-
copy, and barium swallow. Treatment response was ac-
cording to the guidelines for solid tumors [8] as follows: a
complete response (CR) was defined as the complete dis-
appearance of clinically detectable tumor masses; a partial
response (PR) required a >30% decrease in the sum lon-
gest diameter of tumor for at least 1 month; the appear-
ance of new lesions or a 20% increase in the sum longest
diameter of an existing tumor was reported as progressive
disease (PD). Neither PR nor PD criteria met the stan-
dards for stable disease (SD).
Follow-up and statistical analysis
Overall survival and progression-free survival were cal-
culated for each potential prognostic factor with the
Kaplan–Meier method and were measured from the first
day of diagnosis or censored at the date of the last follow-
up. The log-rank test was used for testing significance,
and the level of statistical significance was set at p <0.05.
Multivariate analyses were performed by Cox regression.
The last follow-up evaluation was performed in April
2013. All statistical analyses were performed using SPSS
16.0 software (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Between 2002 and 2011, 139 consecutive patients with
inoperable esophageal squamous cell carcinoma were
studied. The demographic data of the patients are shown
in Table 1. There were 115 (82.7%) male and 24 (17.3%)
female patients with a median age of 63 years (range:
34–86). The median follow-up was 23 months (range:
2–117 months).
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Of the 139 eligible patients, 48 (34.5%) achieved a CR; and
71 (51.1%) patients demonstrated a PR according to the
guidelines for solid tumors, which resulted in a responserate of 76.3%. Nine (6.5%) patients achieved SD and the
remaining 11 patients achieved PD (7.9%).
The 1- 2- and 3-year survival rates were 68.2%, 39.1%,
and 27.9%, respectively; and the 1, 2, and 3 years of
progression-free survival rates were 51.9%, 29.8%, and
20.1%, respectively (Figure 1).
Treatment-related toxicity
Most treatment-related and documented acute toxicities
were grades 1 and 2. The most common grades 3 and 4
toxicities were leukopenia (48 patients; 34.5%) and gastro-
intestinal toxicity (15 patients; 10.8%). Laryngeal edema
occurred in one patient. No therapy-related deaths oc-
curred. Acute treatment-related toxicities were evaluated
based on the CTC 3.0 and are listed in Table 2.
Fifteen patients (10.8%) developed an esophagostenosis
in subsequent follow-up. Radiotherapy-related lung dis-
ease was diagnosed in seven patients (5.0%). One patient
developed paralysis of the vocal cord.
Association of survival and clinicopathologic factors
Univariate analyses were performed for each prognostic
factor. Response to treatment (p <0.001), pathological
grade (p =0.047), T stage (p =0.001), laterality of cervical
lymph nodal metastases (p =0.009), and chemotherapy
regimen (p =0.003) had an effect on overall survival rate
(Table 2). Gender, primary tumor length, radiotherapy
dose, M stage and introduction chemotherapy had no
statistically significant impact on overall survival; it is
worth noting that tumor location approached statistical
significance (p =0.055).
In the univariate analyses of the PFS, response to treat-
ment (p <0.001), pathological grade (p =0.038), T stage
(p =0.002), laterality of cervical lymph nodal metastases
(p =0.006), and chemotherapy regimen (p =0.034) had
an effect on progression-free survival rate. Sex, primary
tumor length, radiotherapy dose, M stage, tumor loca-
tion, and introduction chemotherapy had no statistically
significant impact on progression-free survival.
The 3-year OS of the patients with grade IVa disease
(primary lesions located in the upper-third esophagus)
was 35.9%, which was better than that of the patients with
grade IVb disease (primary lesions located in the middle-
and lower-third of the esophagus), for which the 3-year
OS was 23.0%. However, this difference was not statisti-
cally significant (p =0.086; Figure 2).
Patients who received induced chemotherapy did
not show a benefit in OS (p =0.106; Figure 3A) and
PFS (p =0.253) compared with patients who received
chemoradiotherapy.
After treatment, patients with a CR had an obviously
better prognosis than non-CR patients. The 3-year OS
of patients with a CR was 53.7%; whereas the 3-year OS
of non-CR patients was only 20.1% (p <0.001). The 3-year
Figure 1 Overall survival (A) and progression-free survival (B) according to clinical T stage.
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spectively (p <0.001).
Patients with T1/2 disease had a better 3-year OS than
stage T3 and T4 tumors (36.1% vs. 30.4% vs. 12.5%
p =0.001). The 3-year PFS of patients with T1/T2 dis-
ease was significantly better than that of patients with
T3 and T4 disease (30.7% vs. 21.3% vs. 6.3%; p =0.002).
Patients with unilateral cervical lymph nodal metastases
had a better 3-year OS (33.5%) and a better PFS (26.4%)
compared with those with bilateral metastases (3-year OS
rate, 14.8%, p =0.009; 3-year PFS rate, 4.3%, p =0.006).
The 3-year OS and PFS of patients who received cis-
platin and docetaxel were 37% and 22.7%, respectively.
The 3-year OS and PFS of patients who received cisplatin
and 5-FU were 14.5% and 13.1%, respectively (p =0.003),
while the 3-year OS and PFS rates of patients who re-
ceived other regimens were 13.3% and 11.0%, respectively
(p =0.034).Multivariate analysis
Multivariate analysis was performed for OS, including
factors found to be significant on univariate analysis.
Additionally, a backward stepwise Cox regression analysis
was performed. According to the analysis, response toTable 2 Acute toxicity according to CTC v 3.0
Toxicity Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
n (%) n (%) n (%) n (%) n (%)
Anemia 27 (19.4) 53 (38.1) 52 (37.4) 7 (5.0) 0 (0)
Leukocytopenia 17 (12.2) 44 (31.7) 60 (43.1) 30 (21.6) 18 (12.9)
Thrombopenia 50 (40.0) 45 (32.4) 24 (17.3) 18 (12.9) 2 (1.4)
Gastrointestinal 17 (12.2) 75 (54.0) 32 (23.0) 14 (10.1) 1 (0.7)treatment (p <0.001), clinical T stage (p =0.007), patho-
logical grade (p =0.002), and laterality of cervical lymph
nodal metastases (p =0.023) were independent prognostic
factors for OS. Concurrent chemotherapy (p =0.117) was
not statistically significant.
Discussion
Cervical lymph nodal metastases (CLNM) are not rare
in thoracic esophageal squamous carcinoma. Huang et
al. reported the pattern of thoracic SCC lymph nodal
metastases after esophagectomy. In their study, the rates
of CLNM in patients with upper, middle and lower thor-
acic tumors were 16.7% (9/54), 4.0% (27/680) and 1.0%
(5/343), respectively [9]. It is worth pointing out that
their cases all received surgery and there is an inevitable
operation selection bias. The CLNM rates may be higher
for patients with inoperable SCC treated with chemora-
diotherapy in consideration of more advanced staging.
Previous literature reporting the prognosis of thoracic
esophageal squamous carcinoma with CLNM (stage IV) is
conflicting [2,10]. Shimada et al. retrospectively analyzed
88 patients who were diagnosed with thoracic esophageal
cancer with CLNM and reported that the 5-year OS rate of
these patients was 26% [2]. The Japanese Society for
Esophageal Diseases has divided cervical nodes into four
groups: cervical paraesophageal nodes, deep cervical nodes,
retropharyngeal nodes, and supraclavicular nodes, and in-
volvement of the cervical paraesophageal nodes was de-
fined as stage N1 in the case of cancers of the upper third
of the esophagus [11]. According to the Chinese non-
operative stage of esophageal cancer, patients with CLNM
are considered to be stage N1 (cervical esophageal cancer)
or N2 (thoracic esophageal cancer) [12]. Although patients
with CLNM only were graded as stage IV according to the
Figure 2 Overall survival (A) and progression-free survival (B) according to M stage.
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treatment to expect a better prognosis.
We performed a comprehensive assessment of the effi-
cacy and prognostic factors of chemoradiotherapy for thor-
acic esophageal squamous carcinoma with CLNM only,
and have shown that the prognosis of these patients is not
dismal, despite it being stage IV. In our study, the 3-year
OS and PFS rates of these patients were 27.9% and 20.1%,
respectively. The multivariate analysis showed that re-
sponse to treatment (p <0.001), clinical T stage (p =0.007),
pathological grade (p =0.002), and laterality of cervical
lymph nodal metastases (p =0.023) have a significantFigure 3 Overall survival according to chemotherapy mode (A) and cbearing on overall survival. The main pattern of treatment
failure is still the local recurrence (61/139, 43.9%).
Locoregional control remains the major problem in
patients with SCC treated with chemoradiotherapy. In
our study, patients who achieved a complete response
(CR) had an obviously better survival than those who
did not (non-CR), which is consistent with previous lit-
erature [13,14]. Ohtsu et al. reported that a CR rate of
33% and a 3-year survival rate of 23% were achieved in
patients with unresectable T4 tumors and/or M1 LYM
(lymphatic metastasis) disease. In this study, the chemo-
radiotherapy consisted of a total radiation dose of 60 Gyoncurrent CRT regimen (B).
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(40 mg/m2), followed by two courses of fluorouracil
(800 mg/m2/24 hours for 5 days) and cisplatin (80 mg/
m2 on day 1) [14].
The primary lesion T stage also has a bearing on the
prognosis. In our study, the survival of patients with
T1/2 disease is better than that of those with a T3 le-
sion, and the prognosis of patients with T3 disease is
better than that of those with T4 lesions. Increasing
depth of tumor invasion is associated with the presence
of lymphatic dissemination and thus leads to the
unfavorable prognosis [15]. The same results were
achieved in the analysis of the PFS. In accordance with
our results, Kaneko et al. reported that the prognosis of
patients with T3 lesions was better than that of those
with T4 tumors with squamous cell carcinoma of the
esophagus and concluded that the efficacy and survival
of patients treated with chemoradiotherapy are related
to the T stage [16].
It is worth pointing out that the laterality of the CLNM
has a bearing on the prognosis of patients with thoracic
esophageal squamous carcinoma and CLNM (p =0.023).
The results may be attributed to the fact that patients with
unilateral CLNM have an earlier staging than patients
with bilateral CLNM. Skip metastasis may be another fac-
tor that influences prognosis. Prenzel et al. reported that
skip metastases are associated with better 5-year survival
rates and have a higher rate in cancer of the middle and
upper thirds of the esophagus [17].
The 7th edition AJCC staging system shows that the
tumor location is a component of staging and that the
prognosis of the lower third of esophageal cancer is better
than that of the upper and middle thirds of the esophagus
[18]. In this regard, our data did not reveal a significant
impact for tumor location. However, there were trends ob-
served (p =0.055). This result may be owing to the rela-
tively small number of patients. On the other hand, the
patients with stage IVa disease (primary lesions located in
the upper third of the esophagus) had a better (but not
significant) prognosis than patients with stage IVb disease
(primary lesions located in the middle and lower thirds of
the esophagus), which is in accordance with the 6th AJCC
staging system.
The RTOG 85–01 clinical trial demonstrated that
combined chemoradiotherapy has a significant advan-
tage over radiotherapy only, in patients with esophageal
cancer. But, the concurrent chemotherapy regimen is far
from conclusive [19]. In a phase I trial, Day et al. re-
ported that docetaxel, cisplatin and concurrent radical
radiotherapy is safe and efficient for locally advanced
esophageal cancer with a complete response of 33%. The
progression-free survival at 2 years was 49.7% and at
5 years was 26.5% [20]. In addition, a phase III trial re-
ported that the pathological complete response (pCR) ofpreoperative chemoradiotherapy for esophageal carcin-
oma was 29% and the pCR of esophageal squamous-cell
carcinoma was 49%. These findings reveal that the con-
current carboplatin plus paclitaxel regimen is rather
effective compared with the previous regimen [21]. In a
multicenter phase II trial, a pCR rate of 38% was achieved
in patients with esophageal squamous cell cancer, while
the pCR of patients with adenocarcinoma was only 16%
[22]. In the univariate analyses of our study, the chemo-
therapy regimen had a significant influence on the OS and
PFS (p =0.003 and 0.034, respectively). But, the chemo-
therapy regimen did not reach significance in the multi-
variate analysis (p =0.117). We deduced that this result is
chiefly because of the small number of patients included
in our study.
We did not observe a survival benefit for higher radi-
ation dose when compared with lower radiation dose,
which is in accordance with the results of the INT0123
study. The INT0123 trial reported that a higher radiation
dose did not increase survival or local/regional control in
patients with M0 esophageal cancer (by increasing the ra-
diation dose from 50.4 Gy to 64.8 Gy) with a concurrent
chemotherapy regimen of cisplatin/5-FU [23]. In a phase I/
II trial, Wu et al. reported the treatment effect of patients
with esophageal squamous cell carcinoma who received
three-dimensional conformal radiation therapy. The 2-year
local disease progression-free rate and distant metastasis-
free rate were 36% and 56%, respectively, which were dis-
appointing [24]. Our results also showed that a higher
radiation dose (>60 Gy) did not increase the overall
survival or progression-free survival in the M1 patients
(p =0.107 and 0.605, respectively).
Although numerous studies have indicated that tumor
length influences the prognosis of esophageal cancer
[3,25], the patients in these studies had an earlier stage of
disease. Yendamuri et al. reported that esophageal tumor
length is independently associated with long-term survival,
but found no statistical significance in the stage III patients
[3]. The authors concluded that tumor length may be a
better predictor of locoregional rather than distant control
of disease. In our study, we only included the patients with
stage IV disease. Our findings also reveal that primary
tumor length does not have a significant impact in the
prognostic analysis (p =0.911), which we attribute to
more advanced stages and bulky lesions in our cohort.
The current study is limited by its retrospective design.
Although the cases of cervical lymph nodal metastases in
our study were based on radiology, the specificity of CT in
detecting nodal metastases is 96.7%, and the accuracy is
76.6% for squamous cell carcinoma of the esophagus;
here, nodal enlargement greater than 10 mm was consid-
ered indicative of involvement [26]. Considering these as-
pects of our study, longer follow-up and larger studies are
needed in the future.
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The prognosis of esophageal cancer with CLNM only is
not completely bleak. Concurrent chemoradiotherapy is
an important and hopeful treatment option for these pa-
tients. The response to treatment, T stage, pathological
grade and laterality of cervical lymph nodal metastases
are significant prognostic factors for long-term survival.
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